Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2458

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622458)

Lisdexamfetamine Dimesylate Capsules 70 mg label showing the drug name and strength, packaging quantity of 100 capsules, and Rx only designation. The label includes storage instructions, a barcode, QR codes for package insert and dosage information, and manufacturer details listing Bryant Ranch Prepack as relabeler and Purdue Pharma L.P. as manufacturer.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure of lisdexamfetamine dimesylate showing its molecular components, including an amino group, phenyl ring, and dimesylate moiety. This formula represents the active ingredient in the pharmaceutical product.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A forest plot chart showing pharmacokinetic fold changes and 90% confidence intervals (Cmax and AUC) for special populations including gender, age groups (65-74 years, 75+ years), and varying degrees of renal impairment (mild, moderate, severe, end stage renal disease). The x-axis represents change relative to reference from 0.0 to 2.5.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A chart depicting the pharmacokinetic (PK) fold change and 90% confidence intervals for Cmax and AUC of three drugs—Guanfacine, Venlafaxine, and Omeprazole—relative to a reference. The x-axis represents change relative to reference on a scale from 0.0 to 2.0, with data points and error bars illustrating variability for each parameter.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A chart displaying fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of various interacting drugs relative to a reference. The drugs include Guanfacine, Venlafaxine, caffeine (CYP1A2 substrate), Dextromethorphan (CYP2D6 substrate), Omeprazole (CYP2C19 substrate), and Midazolam (CYP3A substrate). The graph plots change relative to reference on the x-axis (0.0 to 2.0).*

FDA Label Image

Figure 4 (Lisdexcaps 05)

A line graph comparing LS mean SKAMP Deportment Scores over time post-dose in hours for Lisdexamfetamine versus placebo. The graph shows two trend lines, one solid for Lisdexamfetamine and one dashed for placebo, with error bars at each time point from approximately -0.5 to 13 hours.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between two groups: Lisdexamfetamine and Placebo. The y-axis shows the percentage of subjects with relapse or treatment failure, and the x-axis shows time in days, ranging from 0 to 55 days. The graph features a solid line for Lisdexamfetamine and a dashed line for Placebo, with Placebo showing a higher relapse rate over time.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

A line graph comparing LS Mean PERMP Total Scores over time post-dose (hours) between Lisdexamfetamine and placebo groups. The x-axis represents time from slightly before 0 to 14 hours post-dose, and the y-axis shows LS Mean PERMP Total Scores ranging from 250 to 330. Two lines with error bars plot the scores, with Lisdexamfetamine showing a higher score throughout the time period compared to placebo.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A line graph comparing the proportion of subjects with relapse or treatment failure (%) over time (days after randomization) between Lisdexamfetamine and placebo groups. The graph shows two lines: a solid line for Lisdexamfetamine with a lower proportion and a dashed line for placebo with a higher proportion increasing over time, up to 30 days.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

A line graph displaying the proportion of subjects with relapse (%) over time (days after randomization) comparing Lisdexamfetamine and placebo groups. The Lisdexamfetamine group shows a consistently lower relapse rate than the placebo group throughout the study period, which extends to 209 days. The number of subjects at risk for each group is listed below the time axis at multiple time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.